Background: Centralized diagnostics can delay detection of vector-borne pathogens. Molecular point-of-care (mPOC) technologies may address this gap, but performance and field readiness remain uncertain.Methods: This rapid systematic review followed Cochrane Diagnostic Test Accuracy guidance. PubMed, Scopus and Web of Science (Clarivate) were searched for ۲۰۲۰–۲۰۲۵ publications (۱۳ September ۲۰۲۵). Two-by-two data were extracted or reconstructed, and sensitivity and specificity were recalculated with ۹۵% Wilson confidence intervals. Studies were classified by setting, assessed using the real-time connectivity, ease of specimen collection, affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to end-users (REASSURED) criteria, and appraised with Quality Assessment of Diagnostic Accuracy Studies–۲. Heterogeneity led to narrative synthesis.Results: ۱,۹۶۴ records yielded ۲۲ studies: ۱۱ malaria, ۶ leishmaniasis and ۵ arboviral infections. Twenty-one studies provided two-by-two data, yielding ۲۶ non-overlapping analyses. One study reported sensitivity only (۸۶.۴%, ۹۵% confidence interval ۷۵.۵–۹۳.۰%) and one analysis was not reconstructable. Median sample size was ۱۰۰ (interquartile range ۷۶.۵–۱۶۱.۵; range ۱۳–۴۹۰). Thirteen analyses reported ۱۰۰% sensitivity or specificity, but ۹ had lower confidence limits below ۹۰%. Four studies evaluated point-of-care tests. Based on lower confidence limits, ۸ met sensitivity and ۵ met specificity REASSURED thresholds; ۶ met real-time connectivity and ۷ met ease of specimen collection. Seventeen (۷۷.۳%) reported no cost data.Conclusions: mPOC technologies are promising, but evidence is dominated by laboratory or near-laboratory studies with imprecise estimates. Multicenter field evaluations, standardized reporting including costs and complete two-by-two data are needed before integration.Background: Centralized diagnostics can delay detection of vector-borne pathogens. Molecular point-of-care (mPOC) technologies may address this gap, but performance and field readiness remain uncertain.Methods: This rapid systematic review followed Cochrane Diagnostic Test Accuracy guidance. PubMed, Scopus and Web of Science (Clarivate) were searched for ۲۰۲۰–۲۰۲۵ publications (۱۳ September ۲۰۲۵). Two-by-two data were extracted or reconstructed, and sensitivity and specificity were recalculated with ۹۵% Wilson confidence intervals. Studies were classified by setting, assessed using the real-time connectivity, ease of specimen collection, affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to end-users (REASSURED) criteria, and appraised with Quality Assessment of Diagnostic Accuracy Studies–۲. Heterogeneity led to narrative synthesis.Results: ۱,۹۶۴ records yielded ۲۲ studies: ۱۱ malaria, ۶ leishmaniasis and ۵ arboviral infections. Twenty-one studies provided two-by-two data, yielding ۲۶ non-overlapping analyses. One study reported sensitivity only (۸۶.۴%, ۹۵% confidence interval ۷۵.۵–۹۳.۰%) and one analysis was not reconstructable. Median sample size was ۱۰۰ (interquartile range ۷۶.۵–۱۶۱.۵; range ۱۳–۴۹۰). Thirteen analyses reported ۱۰۰% sensitivity or specificity, but ۹ had lower confidence limits below ۹۰%. Four studies evaluated point-of-care tests. Based on lower confidence limits, ۸ met sensitivity and ۵ met specificity REASSURED thresholds; ۶ met real-time connectivity and ۷ met ease of specimen collection. Seventeen (۷۷.۳%) reported no cost data.Conclusions: mPOC technologies are promising, but evidence is dominated by laboratory or near-laboratory studies with imprecise estimates. Multicenter field evaluations, standardized reporting including costs and complete two-by-two data are needed before integration.